Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Incannex Healthcare Limited (IXHL) stock profile

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical-grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and CBD for the prevention and treatment of inflammatory lung conditions such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnerships with The Alfred Hospital and Novotech on the IHL-42X clinical program for obstructive sleep apnea, and with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Key facts

SymbolIXHL
ExchangeNASDAQ
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOJoel Bradley Latham
Employees9
HeadquartersSydney, NSW, AU
IPO2022-03-02
Websitewww.incannex.com.au

Explore IXHL on Vantafin

  • Incannex Healthcare Limited Overview
  • Incannex Healthcare Limited Financials
  • Incannex Healthcare Limited News
  • Incannex Healthcare Limited Events
  • Incannex Healthcare Limited SEC filings
  • Incannex Healthcare Limited Insider transactions

Frequently asked questions

What does Incannex Healthcare Limited (IXHL) do?
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical-grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and CBD for the prevention and treatment of inflammatory lung conditions such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnerships with The Alfred Hospital and Novotech on the IHL-42X clinical program for obstructive sleep apnea, and with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Where is IXHL stock listed?
Incannex Healthcare Limited trades under the ticker IXHL on NASDAQ.
How can I research IXHL's financials and filings?
Vantafin provides Incannex Healthcare Limited's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the IXHL profile.